Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2015

Open Access 01-12-2015 | Clinical Guides in Oncology

Biliary tract cancers: SEOM clinical guidelines

Authors: M. Benavides, A. Antón, J. Gallego, M. A. Gómez, A. Jiménez-Gordo, A. La Casta, B. Laquente, T. Macarulla, J. R. Rodríguez-Mowbray, J. Maurel

Published in: Clinical and Translational Oncology | Issue 12/2015

Login to get access

Abstract

Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.
Literature
1.
Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29.PubMedCrossRef
2.
Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.PubMedCrossRef
3.
Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4:695–706.PubMedCrossRef
4.
Lafaro KJ, Cosgrove D, Geschwind JF, Kamel I, Herman JM, Pawlik TM. Multidisciplinary care of patients with intrahepatic cholangiocarcinoma: updates in management. Gastroenterol Res Pract. 2015;2015:1–14.CrossRef
5.
6.
Masselli G, Manfredi R, Vecchioli A, Gualdi G. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. Eur Radiol. 2008;18:2213–21.PubMedCrossRef
7.
Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol. 2010;45:560–6.PubMedCrossRef
8.
Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21(12):3827–34.PubMedPubMedCentralCrossRef
9.
Ross JS, Wang K, Virgil D, Catenacci T, Chmielecki J, Ali SM, et al. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. J Clin Oncol. 2015;33 Suppl 3:231.
10.
Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9(12):e115383.PubMedPubMedCentralCrossRef
11.
Chan E, Berlin J. Biliary tract cancers: understudied and poorly understood. J Clin Oncol. 2015;33(16):1845–8.PubMedCrossRef
12.
13.
Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget. 2015;6(17):14744–53.PubMedPubMedCentralCrossRef
14.
Kongpetch S, Jusakul A, Ong CK, Lim WK, Rozen SG, Tan P, et al. Pathogenesis of cholangiocarcinoma: from genetics to signaling pathways. Best Pract Res Clin Gastroenterol. 2015;29:233–44.PubMedCrossRef
15.
Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021–31.PubMedPubMedCentralCrossRef
16.
Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144:829–40.PubMedPubMedCentralCrossRef
17.
Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–95.PubMedCrossRef
18.
Hyder O, Marques H, Pulitano C, Marsh JW, Alexandrescu S, Bauer TW, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014;149:432–8.PubMedCrossRef
19.
van der Gaag NA, Kloek JJ, de Bakker JK, Musters B, Geskus RB, Busch OR, et al. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol. 2012;23:2642–94.PubMedCrossRef
20.
Wang SJ, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, et al. Normogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol. 2011;29:4627–32.PubMedPubMedCentralCrossRef
21.
Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–40.PubMedCrossRef
22.
23.
Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, et al. Best supportive care compared with chemotherapy for unresectable gallbladder cancer: a randomized controlled study. J Clin Oncol. 2010;28:4581–6.PubMedCrossRef
24.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gencitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.PubMedCrossRef
25.
Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469–74.PubMedPubMedCentralCrossRef
26.
Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–8.PubMedCrossRef
27.
Lamarca A, Hubner RA, David Ryder W, Valle JW. Second line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25:2328–38.PubMedCrossRef
28.
Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, et al. Multivariate prognostic factors análisis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110:2165–9.PubMedPubMedCentralCrossRef
Metadata
Title
Biliary tract cancers: SEOM clinical guidelines
Authors
M. Benavides
A. Antón
J. Gallego
M. A. Gómez
A. Jiménez-Gordo
A. La Casta
B. Laquente
T. Macarulla
J. R. Rodríguez-Mowbray
J. Maurel
Publication date
01-12-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1436-2

Other articles of this Issue 12/2015

Clinical and Translational Oncology 12/2015 Go to the issue

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

Clinical Guides in Oncology

SEOM guidelines for cervical cancer

Clinical Guides in Oncology

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

Clinical Guides in Oncology

SEOM clinical guidelines in metastatic breast cancer 2015

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits